Company profile
ANAVEX LIFE SCIENCES CORP.
NASDAQ:AVXLBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06245213 | phase2 | active_not_recruiting | 2024-03-15 | 2025-06-30 | Anavex Life Sciences Corp. | A Study of ANAVEX3-71 in Adults With Schizophrenia |
| NCT03774459 | phase2 | completed | 2018-07-09 | 2020-09-30 | Anavex Life Sciences Corp. | ANAVEX2-73 Study in Parkinson's Disease Dementia |
| NCT03941444 | phase3 | completed | 2019-05-06 | 2021-09-30 | Anavex Life Sciences Corp. | ANAVEX2-73 Study in Patients With Rett Syndrome |
| NCT04304482 | phase2_3 | completed | 2020-07-01 | 2023-06-01 | Anavex Life Sciences Corp. | ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome |
| NCT03790709 | phase2_3 | completed | 2018-07-03 | 2022-06-30 | Anavex Life Sciences Corp. | ANAVEX2-73 for Treatment of Early Alzheimer's Disease |
FDA applications (0)
No records yet.